Last reviewed · How we verify
Felodipine add Irbesartan
This combination reduces blood pressure by blocking calcium channels (felodipine) to relax blood vessels and blocking angiotensin II receptors (irbesartan) to reduce vasoconstriction and aldosterone release.
This combination reduces blood pressure by blocking calcium channels (felodipine) to relax blood vessels and blocking angiotensin II receptors (irbesartan) to reduce vasoconstriction and aldosterone release. Used for Hypertension.
At a glance
| Generic name | Felodipine add Irbesartan |
|---|---|
| Also known as | Plendil, Aprovel |
| Sponsor | LanZhou University |
| Drug class | Calcium channel blocker + Angiotensin II receptor blocker combination |
| Target | L-type voltage-gated calcium channels; AT1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Felodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Irbesartan is an angiotensin II receptor blocker (ARB) that antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and sodium retention. Together, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Fatigue
- Flushing
- Hyperkalemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Felodipine add Irbesartan CI brief — competitive landscape report
- Felodipine add Irbesartan updates RSS · CI watch RSS
- LanZhou University portfolio CI